◈ Nootpedia
Compact view
Research pass: medium Peptide · Injectable SKIP-FOR-NOW MEDIUM

Follistatin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

Strong animal hypertrophy signal but failed clinical program (Acceleron ACE-031 cardiac/vascular safety halt, ACE-083 missed efficacy endpoints), thin healthy-adult human evidence, and peptide-vendor identity is questionable for a 30+ kDa glycoprotein that almost certainly cannot survive subQ injection intact. Verdict could shift if a gene-therapy trial demonstrates clean safety in healthy adults or if a credible non-glycosylated peptide mimetic emerges with proper COA chain.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-AT-

    No brain benefit, theoretical cardiac risk during a developmental window, sourcing is identity-fraud territory, and goal of muscle is downstream priority #5 not #1. Free behavioral lever (training + protein + sleep) does most of what this allegedly does, with zero risk.

  • 30-50, executive maintenance
    SKIP

    Same risk/identity issues; no evidence of any benefit relevant to executive function or longevity.

  • 50+, mild cognitive decline
    SKIP

    for cognitive purposes (no relevance). For sarcopenia specifically, watch the gene-therapy + bimagrumab class — but currently no path.

  • Anxiety-prone
    SKIP

    no anxiolytic profile, vascular side effects could spike anxiety.

  • High athletic load, tested status
    SKIP

    WADA-banned (myostatin antagonists are S2 prohibited at all times).

  • Sleep-disordered
    N

    applicable.

  • Recovery-focused (post-injury, post-illness)
    T

    interesting for muscle wasting in cachexia/sarcopenia, but for a healthy 20yo recovering from MMA training load? Massively overkill and risk-mismatched. Skip.

  • Strength/anabolic-focused
    T

    is the only profile where it's even tempting. Even here: failed clinical program + identity-fraud vendor market + cardiac hypertrophy theoretical = the strength-focused 25+yo lifter is better served by AAS or SARMs (worse but at least real and titratable) than by paying $200/vial for what is most likely saline + peptide impurity.

▸ Subjective experience (deep)

For vendor-sourced "follistatin" peptide: Users report nothing acute (no stim, no flush, no sleep effect) and claim slow lean-mass gains over 4-6 weeks. Indistinguishable from placebo + concurrent training adjustment. No reliable subjective marker. This is a flag that either (a) it's not bioactive, or (b) it's so subtle the placebo response dominates.

For ACE-031 trial subjects: Reported nosebleeds and small visible vessel dilations on skin (telangiectasias) within weeks. Lean mass gains were measurable on DXA but functional gains were modest.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown for healthy adults. Theoretically the body could upregulate myostatin or downregulate ActRIIB compensatorily over months. Animal data suggests effect plateaus.
  • Recommended cycle: Not applicable — no evidence-based protocol exists.
  • Reset protocol: N/A.
▸ Stacking deep dive

Synergistic with

  • None evidence-based.
  • Theoretical: training load + protein intake (anything that drives hypertrophy stimulus would compound).

Avoid stacking with

  • Other anabolic agents (AAS, SARMs, GH, IGF-1, MK-677): Compound cardiac hypertrophy risk, compound tendon-mismatch risk, compound HPG suppression.
  • ARBs/ACE inhibitors: Theoretical interaction via shared cardiac remodeling pathways — no human data but caution flag.

Neutral / safe co-administration

  • N/A (not recommending the compound, so co-administration question is moot).
▸ Drug interactions deep dive

No documented CYP interactions (it's a glycoprotein, not a small molecule). The relevant interactions are pharmacodynamic: anything affecting the TGF-β superfamily (BMPs, activins, GDFs) or anything affecting cardiac remodeling (RAAS axis drugs, beta blockers).

▸ Pharmacogenomics
  • MSTN polymorphisms — rare loss-of-function MSTN variants exist (the German child case); carriers might be hypo-responsive to additional myostatin antagonism (already at floor). Common population variants haven't been mapped to follistatin response.
  • ACVR2B polymorphisms — genetic variation in the ActRIIB receptor would theoretically affect response; no commercial test for this on 23andMe.
  • 23andMe will not surface relevant SNPs for this compound.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem peptide Various ("Peptide Sciences", "Core Peptides", many fly-by-night) $60-200/vial (1 mg) Very low Identity questionable — full-length glycosylated FST cannot be made by standard SPPS peptide synthesis; what's sold is likely a truncated peptide fragment, mislabeled, or inactive. No published independent third-party assays of vendor "follistatin" products confirming identity + bioactivity.
Gene therapy (AAV1-FS344) Trial-only (Nationwide Children's, Sarepta) N/A N/A Not available outside enrollment; one-shot irreversible delivery — unsuitable for biohacking even if available.
Recombinant FST for research Sigma, R&D Systems ~$300-1000/100 mcg High (research-grade) Not for human use, not formulated for injection, identity is real but quantity per dose makes cost prohibitive.

Bottom line on sourcing: the peptide-vendor "follistatin" market is the most identity-questionable corner of the gray-market peptide world. Even if the vial contains some peptide, it's almost certainly not bioactive intact follistatin glycoprotein. Belief in vendor product = belief in chain-of-custody from a non-existent legitimate manufacturer.

▸ Biomarkers to track (deep)

If, hypothetically, a credible product existed and someone proceeded:

  • Baseline (before starting): CBC, CMP, lipid panel, fasting glucose/insulin, testosterone (total + free), LH, FSH, AMH (women) / sperm analysis (men), echocardiogram with LV mass measurement, troponin, creatine kinase, DXA scan.
  • During use: Weekly CK + troponin first month; monthly LH/FSH + sex hormones; echo at 12 weeks; DXA at 12 weeks for actual lean mass change vs. baseline (not just scale weight).
  • Post-cycle: LH/FSH/AMH/sperm analysis 3 months post for axis recovery; echo for LV mass regression.
▸ Controversies / open debates Live debate
  • Is vendor-sourced "follistatin" even bioactive? Strong skepticism. Full-length glycosylated FST-315 or FST-344 is a 30+ kDa post-translationally-modified protein that cannot be made by standard solid-phase peptide synthesis. What's actually in vendor vials is unknown — possibly truncated peptide fragments lacking the heparin-binding domain, possibly mislabeled GHRP/IGF-LR3, possibly inert. No published vendor-product mass-spec assay confirming identity. This is the biggest open question and the one that most pushes toward SKIP for biohacking.
  • Does the Acceleron failure generalize? ACE-031 (broad ActRIIB decoy) and ACE-083 (localized FST-Fc fusion) both failed but for different reasons. ACE-031 failed on safety; ACE-083 failed on efficacy translation. Whether full-length systemic follistatin would do better is an open question — but the absence of any company pursuing it suggests insiders don't believe so.
  • AAV gene therapy is the only credible delivery path — but that's a one-shot, not-reversible commitment that's clinically inappropriate for healthy adults with no disease indication.
  • Cardiac hypertrophy: theoretical or real? Animal data is concerning, human ACE-031 trials weren't long enough or large enough to rule it out, but they also didn't show a strong signal. Equipoise here, which for an elective compound = "skip until proven safe."
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-AT-20 MEDIUM confidence. Animal data is impressive but clinical translation has been a graveyard. Peptide vendor identity is the dealbreaker for biohacking even if other concerns were resolvable. Cross-linked to igf-1 and mk-677 as the comparable "anabolic peptide gray-market" cluster — all three share the "real signal, bad sourcing, downstream priority for Dylan" pattern, but follistatin is the worst of the three on identity-verification.
▸ Open questions / gaps Open
  • Vendor product mass-spec data — would a third-party lab confirming identity of common vendor "FST-344" products change the calculus? It might, but only enough to move from "definitely-skip" to "skip-but-possible-with-bloodwork-protocol." Cardiac and reproductive concerns remain.
  • Gene-therapy long-term follow-up — Mendell IBM cohort 5-10 years out. Any cardiac events? Any tumors? (TGF-β family blockade has theoretical cancer-promotion risk.)
  • Bimagrumab post-mortem — why did Novartis kill the program despite Phase 2 lean-mass + fat-loss signal? Unpublished safety signals would be informative.
  • Real efficacy ceiling in trained athletes — all clinical trials were in muscle-wasting populations. Healthy trained adults are likely at much smaller delta from genetic ceiling and might gain very little. Bimagrumab obesity data is the closest proxy and was modest.
▸ Sources (full, with our context)
Back to compact view